“特殊治疗”：必达益尔、塔斯基吉梅毒研究与种族逻辑
"Special treatment": BiDil, Tuskegee, and the logic of race.
作者信息
Reverby Susan M
机构信息
Wellesley College.
出版信息
J Law Med Ethics. 2008 Fall;36(3):478-84. doi: 10.1111/j.1748-720X.2008.294.x.
Abstract
BiDil, a drug approved in 2005 by the FDA only for African Americans, was seen by many as almost reparations for the horrors of the Tuskegee Syphilis Study (1932-72) where treatment for black men was denied. The logic of race, however, rather than racism, links BiDil to the past many thought it was escaping.
摘要
“必存”（BiDil）是一种2005年被美国食品药品监督管理局（FDA）批准仅用于非裔美国人的药物，许多人将其视为对塔斯基吉梅毒研究（1932 - 1972年）中恐怖事件的一种几乎可称为补偿的东西，在该研究中黑人男性被拒绝治疗。然而，将“必存”与过去联系起来的是种族逻辑，而非种族主义，而许多人原本认为它摆脱了过去。
Zotero 插件